NuCana plc (NASDAQ:NCNA) and Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana plc	N/A	0.00	N/A	-0.60	0.00
Sunesis Pharmaceuticals Inc.	N/A	444.82	26.61M	-0.80	0.00

Table 1 demonstrates NuCana plc and Sunesis Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents NuCana plc (NASDAQ:NCNA) and Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS)’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
NuCana plc	0.00%	0%	0%
Sunesis Pharmaceuticals Inc.	0.00%	393.6%	-103.8%

Liquidity

The current Quick Ratio of NuCana plc is 21.2 while its Current Ratio is 21.2. Meanwhile, Sunesis Pharmaceuticals Inc. has a Current Ratio of 1.7 while its Quick Ratio is 1.7. NuCana plc is better positioned to pay off its short-term and long-term debts than Sunesis Pharmaceuticals Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for NuCana plc and Sunesis Pharmaceuticals Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
NuCana plc	0	0	0	0.00
Sunesis Pharmaceuticals Inc.	0	1	1	2.50

On the other hand, Sunesis Pharmaceuticals Inc.’s potential upside is 108.33% and its average target price is $3.25.

Institutional & Insider Ownership

NuCana plc and Sunesis Pharmaceuticals Inc. has shares owned by institutional investors as follows: 34.6% and 33.8%. Insiders owned 15.28% of NuCana plc shares. Competitively, Sunesis Pharmaceuticals Inc. has 0.1% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
NuCana plc	9.97%	-0.46%	-30.08%	-45.98%	-29.7%	-11.03%
Sunesis Pharmaceuticals Inc.	0.28%	5.88%	-41.3%	-73.53%	-91.89%	29.9%

For the past year NuCana plc had bearish trend while Sunesis Pharmaceuticals Inc. had bullish trend.

NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, which is in Phase I clinical trials for the treatment of patients with advanced solid tumors, as well as for the treatment of colorectal and breast cancer; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematology. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. The company was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein BrutonÂ’s tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.